

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DMB

Date	2.24.99
Publication Date	2.25
Certifier	C. WMS. DAI

Food and Drug Administration

Endocrinologic and Metabolic Drugs Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting that is scheduled for March 26, 1999. This meeting was announced in the **Federal Register** of February 8, 1999 (64 FR 6100). The amendment is being made to reflect a change in the agenda of the meeting notice. There are no other changes.


FOR FURTHER INFORMATION CONTACT: Kathleen R. Reedy or LaNise Giles, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12536.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 8, 1999 (64 FR 6100), FDA announced that the meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would discuss experience since approval for marketing, benefits, and risks of Rezulin™ (troglitazone, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) in the treatment of type 2 diabetes mellitus. This amendment is being made to provide new information regarding the agenda of the meeting. On page 6100, in the third column, the *Agenda* is amended to read as follows:

Agenda: The committee will discuss: (1) Experience since approval for marketing, benefits, and risks of Rezulin™ (troglitazone, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) in the treatment of type 2 diabetes mellitus; and (2) new drug application 20-720; S12

Rezulin™ for triple therapy with sulfonylurea and metformin in the treatment of type 2 diabetes mellitus.

Dated: February 16, 1999



Michael A. Friedman
Deputy Commissioner for Operations

[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

BILLING CODE 4160-01-F

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

